ENSC
Ensysce Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.46
+1.24%Next report
Analyst consensus
- Next report date
- Nov 13, 2026
- EPS estimate
- -$0.19
- Revenue estimate
- $1.2M
Latest reported
- Last report date
- Aug 18, 2026
- EPS actual
- -$0.20
- EPS estimate
- -$0.20
- Revenue actual
- $1.2M
- Revenue estimate
- $1.2M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 8
- EPS misses (12Q)
- 3
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +4.4%
- Revenue beats (12Q)
- 3
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 18, 2026 | -$0.20 | -$0.20 | In line | $1.2M |
| May 15, 2026 | -$0.73 | -$0.52 | Beat 28.77% | $961.0K |
| Mar 30, 2026 | -$1.26 | -$0.75 | Beat 40.48% | — |
| Nov 14, 2025 | -$0.85 | -$1.29 | Miss -51.76% | $493.1K |
| Aug 13, 2025 | -$1.02 | -$0.79 | Beat 22.55% | $1.4M |
| Mar 10, 2025 | -$2.74 | -$2.90 | Miss -5.84% | $1.3M |
| Aug 14, 2024 | -$5.85 | -$3.30 | Beat 43.59% | $181.8K |
| May 10, 2024 | -$13 | -$8.25 | Beat 38.84% | $305.7K |
| Mar 15, 2024 | -$13 | -$17 | Miss -31.42% | $515.0K |
| Nov 9, 2023 | -$16 | -$13 | Beat 17.94% | $435.4K |
| Aug 11, 2023 | -$41 | -$15 | Beat 64.11% | $490.5K |
| May 15, 2023 | -$209 | -$31 | Beat 85.05% | $789.6K |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 13, 2026